A ground-breaking new approach to treating chronic Hepatitis B infection and liver cancer that uses cutting-edge mRNA technology is being developed in Melbourne. “Liver patients have a very low survival rate of only 23 per cent; in 2023 there were almost 3,050 new liver cancer diagnoses, and 2,545 people died from the disease,” said Professor Joe Trapani AO, Director, Centre for Cancer Immunotherapy at the VCCC Alliance. |